|
February 23, 2023
|
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
|
|
February 16, 2023
|
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
|
|
January 19, 2023
|
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
|
|
January 9, 2023
|
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
|
|
December 30, 2022
|
Biora Therapeutics Announces Reverse Stock Split
|
|
December 8, 2022
|
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
|
|
November 29, 2022
|
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
|
|
November 14, 2022
|
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
|
|
November 7, 2022
|
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
|
|
November 7, 2022
|
Biora Therapeutics Announces $9.75 Million Direct Offering
|
